Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease

Bone Marrow Transplantation volume 35, pages 699–705 (2005)Cite this article

Summary:

Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m2 was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity profile was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Horowitz MH, Gale RP, Sondel PM et al. Graft-versus-leukemia reaction after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  2. Socié G, Salooja N, Cohen A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385.

    Article  PubMed  Google Scholar 

  3. Sullivan KM . Graft-vs.-host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing Ltd: Malden, 2004, pp 635–664.

    Google Scholar 

  4. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF . A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759–764.

    Article  CAS  PubMed  Google Scholar 

  5. Martin PJ, Carpenter PA, Sanders JE, Flowers ED . Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol 2004; 79: 221–228.

    Article  PubMed  Google Scholar 

  6. Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997; 19: 577–600.

    Article  CAS  PubMed  Google Scholar 

  7. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    CAS  PubMed  Google Scholar 

  8. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821–1828.

    CAS  PubMed  Google Scholar 

  9. Muller-Bérat CN, van Putten LM, van Bekkum DW . Cytostatic drugs in the treatment of secondary disease following homologous bone marrow transplantation: extrapolation from the mouse to the primate. Ann NY Acad Sci 1966; 129: 340–354.

    Article  Google Scholar 

  10. Santos GW, Tutschka PJ, Brookmeyer R et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21–28.

    Google Scholar 

  11. O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–386.

    Article  CAS  PubMed  Google Scholar 

  12. Orchard K, Blackwell J, Chase A et al. Autologous peripheral blood cell transplantation as treatment of severe life-threatening GVHD. Blood 1996; 88 (Suppl. 1): 421 (Abstr. 1673).

    Google Scholar 

  13. Pusic I, Pavletic SZ, Kessinger A et al. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 709–710.

    Article  CAS  PubMed  Google Scholar 

  14. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248–257.

    Article  CAS  PubMed  Google Scholar 

  15. Nousari CH, Brodsky R, Anhalt GJ et al. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 148–150.

    Article  PubMed  Google Scholar 

  16. Petri M, Jones RJ, Brodsky RA . High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 166–173.

    Article  CAS  PubMed  Google Scholar 

  17. Drachman DB, Jones RJ, Brodsky RA . Treatment of refractory myasthemia: ‘rebooting’ with high-dose cyclophosphamide. Ann Neurol 2003; 53: 29–34.

    Article  CAS  PubMed  Google Scholar 

  18. Snowden JA, Passweg J, Moore JJ et al. Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 482–488.

    PubMed  Google Scholar 

  19. Tisdale JF, Dunn DE, Geller N et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomized trial. Lancet 2000; 356: 1554–1559.

    Article  CAS  PubMed  Google Scholar 

  20. Mayer J, Obořilová A, Krejčí M et al. Pulse cyclophosphamide in the treatment of steroid-recfractory GVHD. Bone Marrow Transplant 2003; 31 (Suppl. 1): S185 (Abstr. 534).

    Google Scholar 

  21. Mayer J, Doubek M, Brychtová Y, Krejčí M . Unconventional treatment of steroid-refractory acute GVHD: pulse cyclophosphamide and/or intra-arterial steroid administration. Bone Marrow Transplant 2004; 33 (Suppl. 1): S126 (Abstr. 718).

    Google Scholar 

  22. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  23. Akpek G, Boitnott JK, Lee LA et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903–3907.

    Article  CAS  PubMed  Google Scholar 

  24. Sato T, Sakamaki S, Nagaoka Y et al. Intra-mesenteric artery steroid administration relieved severe refractory gastro-intestinal graft-vs. host disease in an allogeneic bone marrow transplantation patient. Am J Hematol 1997; 56: 277–280.

    Article  CAS  PubMed  Google Scholar 

  25. Shapira MY, Bloom AI, Or R et al. Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Haematol 2002; 119: 760–764.

    Article  CAS  PubMed  Google Scholar 

  26. Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224–1226.

    Article  CAS  PubMed  Google Scholar 

  27. Hsu B, May R, Carrum G et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001; 28: 945–950.

    Article  CAS  PubMed  Google Scholar 

  28. Massenkeil G, Rackwitz S, Genvresse I et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899–903.

    Article  CAS  PubMed  Google Scholar 

  29. McCaul KG, Nevill TJ, Barnett MJ et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367–374.

    Article  CAS  PubMed  Google Scholar 

  30. Khoury H, Kashyap A, Adkins DR et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059–1064.

    Article  CAS  PubMed  Google Scholar 

  31. Remberger M, Aschan J, Barkholt J et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147–153.

    Article  CAS  PubMed  Google Scholar 

  32. Arai S, Margolis J, Zahurak M et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155–160.

    Article  PubMed  Google Scholar 

  33. Van Lint MT, Uderzo C, Milone G et al. A GITMO randomized trial in steroid refractory acute graft-versus-host disease: 6-methylprednisolone with or without anti-thymocyte globulin. Bone Marrow Transplant 2004; 33 (Suppl. 1): S45 (Abstr. 281).

    Google Scholar 

  34. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    CAS  PubMed  Google Scholar 

  35. Couriel D, Saliba R, Hicks KC et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.

    Article  CAS  PubMed  Google Scholar 

  36. Carpenter PA, Appelbaum FR, Corey L et al. A humanized non-FcR-binding anti-CD3 antibody. visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712–2719.

    Article  CAS  PubMed  Google Scholar 

  37. Biersack H, Trenschel R, Peceny R et al. Treatment of steroid refractory acute GVHD with Campath-1H. Bone Marrow Transplant 2004; 33 (Suppl. 1): S188 (Abstr. P726).

    Google Scholar 

  38. Nash RA, Furlong T, Storb R et al. Mycophenolate mofetil as salvage treatment for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Safety analysis. Blood 1997; 90 (Suppl. 1): 328 (Abstr. 459).

    Google Scholar 

  39. Benito AI, Furlong T, Martin PJ et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924–1929.

    Article  CAS  PubMed  Google Scholar 

  40. Bolanos-Meade J, Jacobsohn D, Margolis J et al. Pentostatin in steroid refractory acute graft versus host disease. Blood 2002; 100: 420a (Abstr. 1628).

    Article  Google Scholar 

  41. MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387–394.

    Article  CAS  PubMed  Google Scholar 

  42. Messner HA, Curtis JE, Minden MD et al. Clonogenic hemopoietic precursors in bone marrow transplantation. Blood 1987; 70: 1425–1432.

    CAS  PubMed  Google Scholar 

  43. Benboubker L, Cartron G, Roingeard F et al. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte–macrophage colony-stimulating factor compared to bone marrow. Exp Hematol 2003; 31: 89–97.

    Article  CAS  PubMed  Google Scholar 

  44. Ravagnani F, Siena S, Bragni M et al. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Br J Cancer 1990; 26: 562–564.

    CAS  Google Scholar 

  45. Jones RJ, Barber JP, Vala MS et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85: 2742–2746.

    CAS  PubMed  Google Scholar 

  46. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a Research Grant of the Ministry of Health of the Czech Republic No. MZ 00065269705.

Author information

Authors and Affiliations

  1. Department of Internal Medicine – Hemato-oncology, University Hospital Brno, Brno, Czech Republic

    J Mayer, M Krejčí, M Doubek, Y Brychtová, M Tomíška & Z Ráčil

  2. Department of Applied Mathematics, Masaryk University, Brno, Czech Republic

    Z Pospíšil

Authors
  1. J Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Krejčí
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Doubek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z Pospíšil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Brychtová
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Tomíška
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z Ráčil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mayer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayer, J., Krejčí, M., Doubek, M. et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 35, 699–705 (2005). https://doi.org/10.1038/sj.bmt.1704829

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704829

Keywords

This article is cited by

Search

Advanced search

Quick links